HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ZP120

a nociceptin/orphanin FQ receptor ligand

Also Known As:

Ac-RYYRWKKKKKKK-NH2; SER100

Networked: 5 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - ZP120: 5

Experts

1.	Gulbrandsen, Trygve: 2 articles (11/2017 - 12/2016)
2.	Caló, Girolamo: 1 article (01/2019)
3.	Guerrini, Remo: 1 article (01/2019)
4.	Preti, Delia: 1 article (01/2019)
5.	Marzoli, Francesca: 1 article (01/2018)
6.	Mustazza, Carlo: 1 article (01/2018)
7.	Pieretti, Stefano: 1 article (01/2018)
8.	Kantola, Ilkka: 1 article (11/2017)
9.	Meland, Nils: 1 article (11/2017)
10.	Scheinin, Mika: 1 article (11/2017)

Related Diseases

1.	Hyponatremia 08/01/2005 - "Together, these findings demonstrate that ZP120 is a novel, functionally selective SIP-modified NOP receptor partial agonist with increased biological activity and sodium-potassium-sparing aquaretic activity, the actions of which may be useful in the management of hyponatremia/hypokalemia in water-retaining states."
2.	Hypokalemia 08/01/2005 - "Together, these findings demonstrate that ZP120 is a novel, functionally selective SIP-modified NOP receptor partial agonist with increased biological activity and sodium-potassium-sparing aquaretic activity, the actions of which may be useful in the management of hyponatremia/hypokalemia in water-retaining states."
3.	Overactive Urinary Bladder (Overactive Bladder) 01/01/2019 - "The diverse approaches led to the identification of important pharmacological tools along with drug candidates currently in clinical development such as Rec 0438 (aka UFP-112) for the treatment of overactive bladder and SER 100 (aka ZP120) for the clinical management of systolic hypertension." 01/01/2018 - "Furthermore, the partial agonist peptide SER100 and N/OFQ have been used in clinical trials, respectively for congestive heart failure and overactive bladder. "
4.	Isolated Systolic Hypertension 01/01/2019 - "The diverse approaches led to the identification of important pharmacological tools along with drug candidates currently in clinical development such as Rec 0438 (aka UFP-112) for the treatment of overactive bladder and SER 100 (aka ZP120) for the clinical management of systolic hypertension." 11/01/2017 - "The purpose of the present trial was to evaluate safety, tolerability, and effect on systolic blood pressure (SBP) of SER100 in a small group of patients with isolated systolic hypertension (ISH) in treatment with at least 1 antihypertensive drug. " 11/01/2017 - "Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension."
5.	Tachycardia (Tachyarrhythmias) 08/01/2005 - "In vivo, dose-response studies in rats showed that at doses (i.v. bolus or i.v. infusion) that produced a sodium-potassium-sparing aquaresis, ZP120 and Ac-RYYRWK-NH(2) elicited a mild vasodilatory response without reflex tachycardia. "

Related Drugs and Biologics

1.	Sodium
2.	Potassium
3.	Peptides (Polypeptides)
4.	Antihypertensive Agents (Antihypertensives)
5.	Nociceptin Receptor